3D Vaxlock Technology Achieves Unprecedented Potent Immune Response

Calder Biosciences, Inc. announced today that the journal Nature Communications published an article that debuts and validates the application of Calder's '3D Vaxlock' platform technology.

When applied to the Respiratory Syncytial Virus (RSV) F protein as a vaccine immunogen, Calder's 3D Vaxlock technology achieves an unprecedented 11X more potent immune response than the standard industry comparator. 

The 11-fold higher responses are measured in terms of antibodies generated that neutralize the virus on contact, thus preventing infection.

The technology's application shows that the prefusion conformation of RSV fusion protein can be stabilized with two engineered dityrosine crosslinks (DT-preF), markedly improving its stability and shelf-life.

Calder's vaccine also demonstrates improvements in the quality of elicited immune responses since a greater proportion of the antibodies neutralize the virus.

"There remains an urgent need for vaccines that provide good protection for 75+ older adults and the frail. Protecting newborn children for a longer period through maternal vaccination also remains an important goal," said Florian Schödel, MD, a Calder's Scientific Advisory Board member, in a press release on March 13, 2024.

In addition to the RSV program, Calder is applying its technology to Universal Influenza and Epstein-Barr virus vaccines.

The Nature Communications manuscript is linked here.